Spark Investment Management’s Prelude Therapeutics PRLD Stock Holding History

Spark Investment Management’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.5K	Buy	+10,600	New	+$46.1K	0.11%	56

Other funds holding PRLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Spark Investment Management's PRLD Position: Q2 2026 in Review

Spark Investment Management opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 10,600 shares worth $56.5K. The stake represents 0.11% of the portfolio and ranks #56 among its holdings.

19 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

Spark Investment Management held 10,600 shares of Prelude Therapeutics worth $56.5K as of Q2 2026.
Prelude Therapeutics was a new Spark Investment Management position in Q2 2026.
Prelude Therapeutics made up 0.11% of Spark Investment Management's portfolio in Q2 2026, its #56 holding.
19 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Spark Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.